Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priel

Showing results (411-420 of 433) with videos related to

Pageof 44
Sort By:
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
Blood|December 31, 2009
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasiaDonald C Vinh, Smita Y Patel, Gulbu Uzel, et al.
Cell|February 10, 2015
Chromothriptic cure of WHIM syndromeDavid H McDermott, Ji-Liang Gao, Qian Liu, et al.
Blood|February 14, 2014
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforDavid H McDermott, Qian Liu, Daniel Velez, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
American Journal of Human Genetics|July 1, 2014
Integrative DNA, RNA, and protein evidence connects TREML4 to coronary artery calcificationShurjo K Sen, Kimberly C Boelte, Jennifer J Barb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade AstrocytomasJing Wu, Ying Yuan, Debra A Long Priel, et al.
The Journal of Allergy and Clinical Immunology|April 2, 2013
Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosisElizabeth P Sampaio, Amy P Hsu, Joseph Pechacek, et al.
Blood Cells, Molecules & Diseases|June 27, 2021
Hematologically important mutations: X-linked chronic granulomatous disease (fourth update)Dirk Roos, Karin van Leeuwen, Amy P Hsu, et al.
Blood Cells, Molecules & Diseases|September 21, 2021
Hematologically important mutations: The autosomal forms of chronic granulomatous disease (third update)Dirk Roos, Karin van Leeuwen, Amy P Hsu, et al.
Pageof 44

Showing results (411-420 of 433) with videos related to

Sort By:
Pageof 44
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
Blood|December 31, 2009
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasiaDonald C Vinh, Smita Y Patel, Gulbu Uzel, et al.
Cell|February 10, 2015
Chromothriptic cure of WHIM syndromeDavid H McDermott, Ji-Liang Gao, Qian Liu, et al.
Blood|February 14, 2014
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforDavid H McDermott, Qian Liu, Daniel Velez, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
American Journal of Human Genetics|July 1, 2014
Integrative DNA, RNA, and protein evidence connects TREML4 to coronary artery calcificationShurjo K Sen, Kimberly C Boelte, Jennifer J Barb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade AstrocytomasJing Wu, Ying Yuan, Debra A Long Priel, et al.
The Journal of Allergy and Clinical Immunology|April 2, 2013
Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosisElizabeth P Sampaio, Amy P Hsu, Joseph Pechacek, et al.
Blood Cells, Molecules & Diseases|June 27, 2021
Hematologically important mutations: X-linked chronic granulomatous disease (fourth update)Dirk Roos, Karin van Leeuwen, Amy P Hsu, et al.
Blood Cells, Molecules & Diseases|September 21, 2021
Hematologically important mutations: The autosomal forms of chronic granulomatous disease (third update)Dirk Roos, Karin van Leeuwen, Amy P Hsu, et al.
Pageof 44